DarioHealth Corp. Files 8-K

TL;DR

DarioHealth filed an 8-K, likely a routine update, check for details.

AI Summary

DarioHealth Corp. filed an 8-K on March 1, 2024, to report other events. The company, formerly known as LabStyle Innovations Corp., is incorporated in Delaware and headquartered in New York. The filing does not contain specific details about the 'other events' but serves as a notification to the SEC.

Why It Matters

This filing indicates DarioHealth Corp. has made a regulatory submission to the SEC, which could precede or follow significant corporate actions or disclosures.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose specific material information that would immediately impact risk.

Key Players & Entities

• DarioHealth Corp. (company) — Registrant
• LabStyle Innovations Corp. (company) — Former company name
• March 1, 2024 (date) — Date of report
• New York (location) — Principal Executive Offices
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share DRIO The Nasdaq Capital M
• $1,000 — eferred Stock"), at a purchase price of $1,000 for each share of Preferred Stock. In a
• $22,422,000 — gregate gross proceeds of approximately $22,422,000. The Company does not intend to conduct

Filing Documents

• tm247774d1_8k.htm (8-K) — 24KB
• 0001104659-24-029961.txt ( ) — 192KB
• drio-20240301.xsd (EX-101.SCH) — 3KB
• drio-20240301_lab.xml (EX-101.LAB) — 33KB
• drio-20240301_pre.xml (EX-101.PRE) — 22KB
• tm247774d1_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. As previously reported, on February 15, 2024, DarioHealth Corp. (the "Company") entered into a securities purchase agreement with accredited investors relating to an offering (the "Offering") and the sale of an aggregate of (i) 17,307 shares of newly designated Series C Preferred Stock (the "Series C Preferred Stock"), and (ii) 4,000 shares of Series C-1 Preferred Stock (the "Series C-1 Preferred Stock"), at a purchase price of $1,000 for each share of Preferred Stock. In addition, on February 16, 2024, the Company entered into a securities purchase agreement with accredited investors relating to the Offering and the sale of an aggregate of 1,115 shares of Series C-2 Preferred Stock (the "Series C-2 Preferred Stock" and together with the Series C Preferred Stock and the Series C-1 Preferred Stock, the "Preferred Stock"), at a purchase price of $1,000 for each share of Preferred Stock. The Company retained Aegis Capital Corp. as placement agent for the Offering. On February 21, 2024, the Company closed the Offering, resulting in aggregate gross proceeds of approximately $22,422,000. The Company does not intend to conduct any further closings with respect to the Offering.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 1, 2024 DARIOHEALTH CORP. By: /s/ Zvi Ben David Name: Zvi Ben David Title: Chief Financial Officer, Treasurer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR